Beranda › Leukemia Biphenotypic Akut › Idaho › Boise
Uji klinis Leukemia Biphenotypic Akut di Boise, ID
3 studi untuk Leukemia Biphenotypic Akut mencari peserta di lokasi sekitar Boise (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Menerima pesertaFase 2
- Saint Luke's Cancer Institute - Boise, Boise
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Menerima pesertaFase 3
- Saint Luke's Cancer Institute - Boise, Boise
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Menerima pesertaFase 1/2
- Saint Luke's Cancer Institute - Boise, Boise
Uji klinis Leukemia Biphenotypic Akut di kota lain
- Seattle, WA15 studi
- Houston, TX11 studi
- New York City, NY10 studi
- Atlanta, GA9 studi
- Durham, NC8 studi
- Memphis, TN7 studi
- Chicago, IL7 studi
- Charlotte, NC6 studi
- Aurora, CO6 studi
- Baldwin Park, CA6 studi
- Portland, OR6 studi
- Los Angeles, CA6 studi
Studi lain di Boise
- Kanker Paru Non-Sel Kecil14 studi
- Kanker Paru11 studi
- Kanker Prostat8 studi
- Leukemia Mieloid Akut8 studi
- Kanker Kolon7 studi
- Kanker Payudara6 studi
- Melanoma6 studi
- Kanker Kolorektal6 studi
- Sindrom Distres Respirasi6 studi
- Limfoma Burkitt5 studi
- Cedera Otak Traumatik4 studi
- Sindrom Pasca-Konkusi4 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.